A
Adrienne Kuxhausen
Publications - 4
Citations - 272
Adrienne Kuxhausen is an academic researcher. The author has contributed to research in topics: Booster dose & Internal medicine. The author has an hindex of 1, co-authored 1 publications receiving 223 citations.
Papers
More filters
Journal ArticleDOI
Cost and Mortality Associated With Postoperative Acute Kidney Injury
Charles Hobson,Tezcan Ozrazgat-Baslanti,Adrienne Kuxhausen,Paul Thottakkara,Philip A. Efron,Frederick A. Moore,Lyle L. Moldawer,Mark S. Segal,Azra Bihorac +8 more
TL;DR: Hospital costs and mortality are strongly associated with postoperative AKI, are correlated with the severity ofAKI, and are much higher for patients with other postoperative complications in addition to AKI.
Journal ArticleDOI
No Immunological Interference or Safety Concerns When Adjuvanted Recombinant Zoster Vaccine Is Coadministered With a Coronavirus Disease 2019 mRNA-1273 Booster Vaccine in Adults Aged 50 Years and Older: A Randomized Trial
Abdi Naficy,Adrienne Kuxhausen,P. Pirrotta,Brett Leav,Jacqueline Miller,Kate O Anteyi,Jasur Danier,Thomas Breuer,A. Mwakingwe-Omari +8 more
TL;DR: In this article , a randomized, open-label study, eligible adults aged ≥50 years were randomly assigned (1:1) to receive mRNA-1273 (50µg) booster vaccination and a first dose of recombinant zoster vaccine (RZV1) 2 weeks apart (Seq group) or concomitantly (Coad group).
Journal ArticleDOI
No safety concerns observed when the adjuvanted recombinant zoster vaccine (rzv) and the covid-19 mrna-1273 booster were co-administered in ≥50-year-olds
Posted ContentDOI
No immunological interference or safety concerns when adjuvanted recombinant zoster vaccine is coadministered with a COVID-19 mRNA-1273 booster vaccine in adults aged 50 years and older: A randomized trial
Abdi Naficy,Adrienne Kuxhausen,P. Pirrotta,Brett Leav,Kate O Anteyi,Matthew Adams,Jasur Danier,Thomas Breuer,A. Mwakingwe-Omari +8 more
TL;DR: In this paper , a randomized, open-label study, eligible adults aged 50 years were randomly assigned (1:1) to receive mRNA-1273 (50g) booster vaccination and a first dose of recombinant zoster vaccine (RZV1) 2 weeks apart (Seq group) or concomitantly (Coad group).